Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

Alleviating anastrozole induced bone toxicity by selenium nanoparticles in SD rats.

Vekariya KK, Kaur J, Tikoo K.

Toxicol Appl Pharmacol. 2013 Apr 15;268(2):212-20. doi: 10.1016/j.taap.2013.01.028. Epub 2013 Feb 13.

PMID:
23415680
[PubMed - indexed for MEDLINE]
2.

A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.

Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS, Evans DB.

Bone. 2006 Oct;39(4):787-95. Epub 2006 Jul 17.

PMID:
16844441
[PubMed - indexed for MEDLINE]
3.

A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.

McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.

Breast Cancer Res Treat. 2010 Feb;119(3):643-51. doi: 10.1007/s10549-009-0646-0.

PMID:
19941160
[PubMed - indexed for MEDLINE]
4.

Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.

Leder BZ, Finkelstein JS.

Osteoporos Int. 2005 Dec;16(12):1487-94. Epub 2005 Apr 23.

PMID:
15856361
[PubMed - indexed for MEDLINE]
5.

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).

Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group.

J Bone Miner Res. 2006 Aug;21(8):1215-23.

PMID:
16869719
[PubMed - indexed for MEDLINE]
6.

ERα signaling imparts chemotherapeutic selectivity to selenium nanoparticles in breast cancer.

Vekariya KK, Kaur J, Tikoo K.

Nanomedicine. 2012 Oct;8(7):1125-32. doi: 10.1016/j.nano.2011.12.003. Epub 2011 Dec 23.

PMID:
22197727
[PubMed - indexed for MEDLINE]
7.

Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats.

Sampath TK, Simic P, Sendak R, Draca N, Bowe AE, O'Brien S, Schiavi SC, McPherson JM, Vukicevic S.

J Bone Miner Res. 2007 Jun;22(6):849-59.

PMID:
17352644
[PubMed - indexed for MEDLINE]
8.

Side effects of anastrozole in the experimental pre-menopausal mammary carcinogenesis.

Sadlonova V, Kubatka P, Kajo K, Ostatnikova D, Nosalova G, Adamicova K, Sadlonova J.

Neoplasma. 2009;56(2):124-9.

PMID:
19239326
[PubMed - indexed for MEDLINE]
9.

Collaborative work on evaluation of ovarian toxicity. 8) Two- or four-week repeated-dose studies and fertility study of Anastrozole in female rats.

Shirai M, Sakurai K, Saitoh W, Matsuyama T, Teranishi M, Furukawa T, Sanbuissho A, Manabe S.

J Toxicol Sci. 2009;34 Suppl 1:SP91-9.

PMID:
19265294
[PubMed - indexed for MEDLINE]
Free Article
10.

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.

Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.

PMID:
17618847
[PubMed - indexed for MEDLINE]
11.

Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.

McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R.

Eur J Cancer. 2007 Nov;43(17):2523-31.

PMID:
18029171
[PubMed - indexed for MEDLINE]
12.

Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.

Wang J, Zhang Q, Jin S, Feng M, Kang X, Zhao S, Liu S, Zhao W.

Exp Gerontol. 2009 Jun-Jul;44(6-7):398-405. doi: 10.1016/j.exger.2009.03.003. Epub 2009 Mar 17.

PMID:
19298850
[PubMed - indexed for MEDLINE]
13.

The effects of anastrozole on neonatal rat skin.

Akcali C, Inaloz S, Karakok M, Demirtas OC, Kirtak N, Inaloz S.

Eur J Gynaecol Oncol. 2007;28(6):534-6.

PMID:
18179158
[PubMed - indexed for MEDLINE]
14.

Chemopreventive effects of anastrozole in a premenopausal breast cancer model.

Kubatka P, Sadlonová V, Kajo K, Nosál'ová G, Ostatníková D, Adamicová K.

Anticancer Res. 2008 Sep-Oct;28(5A):2819-23.

PMID:
19035316
[PubMed - indexed for MEDLINE]
Free Article
15.

Effects of letrozole on bone biomarkers and femur fracture in female rats.

Yonden Z, Aydin M, Alcin E, Kelestemur MH, Kutlu S, Yilmaz B.

J Physiol Biochem. 2009 Sep;65(3):267-75. doi: 10.1007/BF03180579.

PMID:
20119821
[PubMed - indexed for MEDLINE]
16.

Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.

Goss PE, Qi S, Cheung AM, Hu H, Mendes M, Pritzker KP.

Clin Cancer Res. 2004 Sep 1;10(17):5717-23.

PMID:
15355898
[PubMed - indexed for MEDLINE]
Free Article
17.

Effect of D-003, a mixture of very high molecular weight aliphatic acids, on prednisolone-induced osteoporosis in Sprague-Dawley rats.

Noa M, Mendoza S, Más R, Mendoza N, León F.

Drugs R D. 2004;5(5):281-90.

PMID:
15357627
[PubMed - indexed for MEDLINE]
18.

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.

Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.

J Clin Oncol. 2010 Feb 20;28(6):967-75. doi: 10.1200/JCO.2009.24.5902. Epub 2010 Jan 11.

PMID:
20065185
[PubMed - indexed for MEDLINE]
19.

In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague-Dawley rats by ormeloxifene, a selective estrogen receptor modulator.

Arshad M, Sengupta S, Sharma S, Ghosh R, Sawlani V, Singh MM.

J Steroid Biochem Mol Biol. 2004 Jun;91(1-2):67-78.

PMID:
15261309
[PubMed - indexed for MEDLINE]
20.

Protective effect of egg yolk peptide on bone metabolism.

Kim HK, Lee S, Leem KH.

Menopause. 2011 Mar;18(3):307-13. doi: 10.1097/gme.0b013e3181f31b1f.

PMID:
21107301
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk